ThomasHerzogMD
Obstetrics & Gynecology • Cincinnati, OHGynecologic Oncology
Professor of Obstetrics & Gynecology, Columbia P&S
Dr. Herzog is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2139 Auburn Ave
Cincinnati, OH 45219Phone+1 513-585-2323Fax+1 513-585-4893
Education & Training
Washington University/B-JH/SLCH ConsortiumFellowship, Gynecologic Oncology, 1990 - 1993
TriHealth (Bethesda North and Good Samaritan Hospitals)Residency, Obstetrics and Gynecology, 1986 - 1990
University of Cincinnati College of MedicineClass of 1986
Certifications & Licensure
OH State Medical License 1988 - 2026
NY State Medical License 2004 - 2015- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2008-2014
- New York Magazine: Top Doctors Castle Connolly, 2007-2014
- Top Doctors: New York Metro Area Castle Connolly, 2007-2013
- Join now to see all
Publications & Presentations
PubMed
- 16 citationsDoes adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncolo...Alexander B. Olawaiye, James J. Java, Thomas C. Krivak, Michael Friedlander, David G. Mutch
Gynecologic Oncology. 2018-10-01 - 375 citationsRobotically assisted vs laparoscopic hysterectomy among women with benign gynecologic diseaseJason D. Wright, Cande V. Ananth, Sharyn N. Lewin, William M. Burke, Yu Shiang Lu
JAMA. 2013-02-20 - 7 citationsENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer.Rodney P Rocconi, Laura Stanbery, Min Tang, Luciana Madeira da Silva, Adam Walter
Communications Medicine. 2022-01-01
Other
- Adjuvant therapy of early stage (stage I and II) epithelial ovarian, fallopian tubal, or peritoneal cancerHerzog TJ
http://www.uptodate.com/contents/adjuvant-therapy-of-early-stage-stage-i-and-ii-epithelial-ovarian-f
UpToDate, Wolters Kluwer Health - 2012-11-13 - First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancerHerzog TJ
http://www.uptodate.com/contents/first-line-chemotherapy-for-advanced-stage-iii-or-iv-epithelial-ova
UpToDate, Wolters Kluwer Health - 2013-04-08
Press Mentions
Alkermes Announces Two Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingMay 9th, 2023- Alkermes to Present Data on Nemvaleukin Alfa at the Society of Gynecologic Oncology 2022 Annual Meeting on Women’s CancerFebruary 24th, 2022
- Combo Tx Active in Recurrent, Platinum-Resistant Ovarian CancerMarch 26th, 2021
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
